Investigation Report on China Budesonide Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||296859|
|出版日期||內容資訊||英文 30 Pages
|中國的Budesonide市場分析 Investigation Report on China Budesonide Market, 2010-2019|
|出版日期: 2015年06月11日||內容資訊: 英文 30 Pages||
Budesonide的吸入停止(商標名「Pulmicort Respules」)由Astra Zeneca開發，作為氣喘的治療藥2000年獲得美國FDA(食品藥物管理局)銷售認證。中國在2001年也獲得認證。在中國國內現在呼吸系統疾病的患者約有3億人，其中5,000萬人主訴咳嗽的症狀，一年增加4％的比例。還有1,500∼2,000萬人患氣喘病。因此中國的Budesonide市場年複合成長率(CAGR)(2005∼2014年)達到29％，依然有莫大需求。
With the climatic and environmental changes, seasonal asthma has become the main reason for respiratory ailments. According to an epidemiological survey, the incidence of respiratory ailments is 16% of the incidence of all diseases. About 280 million people in the world suffer from different degrees of seasonal asthma, more so in industrialized countries and regions where tobacco consumption is high. 5% of adults and 20% of children there have been attacked by this disease and many of them come down with bronchial asthma induced by chronic cough.
Nearly 300 million people in China contract respiratory ailments, among which over 50 million suffer from cough with an annual growth rate of 4% and 15-20 million asthma.
Budesonide, an adrenocortical hormone, was developed by Astrazeneca in the 1990s. It is mainly used for the treatment of non-glucocorticoid dependent or glucocorticoid-dependent bronchial asthma and chronic obstructive pulmonary disease (COPD). In Jun. 1997, budesonide aerosol got FDA's approval. In recent years, with the steady growth of global demand, budesonide has occupied an important position in the TOP10 respiratory drugs.
In 1994, China approved the import of budesonide for clinical purposes. After being marketed by Astra (Wuxi) in China in 1995, budesonide develops fast with annual sales rising from CNY 60 million in 2005 to CNY 595 million in 2014 and CAGR reaching up to 29% during the period of 2005-2014. Budesonide enjoys a vast demand in China. Currently, budesonide in the Chinese market mainly come from the following companies: Lunan Better Pharmaceutical Co., Ltd, Orion Corporation (Finland), WELLCOME AUSTRALIA LTD.(AU), SYNMOSA BIOPHARMA CORPORATION (TW) and Astra AB (Sweden). While they all take up certain shares in the market, WELLCOME AUSTRALIA LTD.(AU) has the largest market share of 88% with sales value reaching up to CNY 524 million in 2014.
The market size of budesonide in China is expected to keep growing in the next few years.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: